Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
- 1 March 2009
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (4) , 601-607
- https://doi.org/10.1016/j.ejca.2008.11.006
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Time Trend and Geographic Patterns of Lung Adenocarcinoma in the United States, 1973-2002Cancer Epidemiology, Biomarkers & Prevention, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- 180 Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin (C), vindesin (V), mitomycin (M) chemotherapyLung Cancer, 1997
- Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986